Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

News | Antiplatelet and Anticoagulation Therapies | November 16, 2017

November 16, 2017 — Bristol-Myers Squibb Company and Pfizer Inc. released real-world data (RWD) of outcomes...

News | Heart Failure | November 13, 2017

November 10, 2017 — Moderna Therapeutics announced a new license and collaboration with AstraZeneca to co-develop...

Six Months of DAPT Non-Inferior to Twelve in STEMI Patients Receiving Drug-Eluting Stents. Photo courtesy of Siemens Healthineers

Photo courtesy of Siemens Healthineers

News | Antiplatelet and Anticoagulation Therapies | November 06, 2017

November 6, 2017 —  The first trial to evaluate the safety of...

Synergy Stent With Shorter DAPT Superior to Bare-Metal Stent in Elderly Patients
News | Stents Drug Eluting | November 06, 2017

November 6, 2017 — Elderly patients undergoing...

Statins Attributed With 10-Year Cholesterol Drop for Malaysian Heart Attack Patients
News | Antiplatelet and Anticoagulation Therapies | November 03, 2017

November 3, 2017 — A ten-year decline in the blood cholesterol of heart attack patients in Malaysia suggests...

Three-Month DAPT Non-Inferior for ACS Patients Treated With Combo Dual Therapy Stent

Image courtesy of OrbusNeich

News | Stents Drug Eluting | November 01, 2017

November 1, 2017 — OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at...

FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents | October 27, 2017

October 27, 2017 — CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved...

News | Stem Cell Therapies | October 24, 2017

October 24, 2017 — Roche and Ncardia have reached a broad licensing agreement whereby Roche and its affiliate...

Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017

October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...

News | Pharmaceuticals | October 04, 2017

October 4, 2017 — MyoKardia Inc. recently provided a clinical update on its MYK-491 program for dilated...

Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure | September 19, 2017

September 19, 2017 — The heart failure...

News | Pharmaceuticals | September 12, 2017

September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in...

New FOURIER Analysis Examines How Low Cholesterol Can Safely Go
News | ESC | September 12, 2017

September 12, 2017 — Very aggressive reduction of LDL-cholesterol to ultra-low levels was associated with...

CANTOS Study Shows Reducing Inflammation Cuts Cardiovascular Disease, Lung Cancer Risk
News | ESC | September 12, 2017

September 12, 2017 — The IL-1β inhibitor canakinumab lowers the risk of cardiovascular disease and lung cancer risk...

COMPASS Trial Shows Rivaroxaban With Aspirin Improves Stable Cardiovascular Disease
Feature | Antiplatelet and Anticoagulation Therapies | September 12, 2017

September 12, 2017 — Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with...

Overlay Init